Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
Authors
Keywords
Atrial Fibrillation, Warfarin, International Normalize Ratio, Apixaban, Probabilistic Sensitivity Analysis
Journal
American Journal of Cardiovascular Drugs
Volume 17, Issue 2, Pages 123-133
Publisher
Springer Nature
Online
2016-11-24
DOI
10.1007/s40256-016-0204-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Resource utilization and costs for treatment of stroke patients in an acute stroke unit in Greece
- (2016) Persefoni Kritikou et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States
- (2015) Mintu P. Turakhia et al. AMERICAN JOURNAL OF CARDIOLOGY
- A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
- (2015) Rubén Casado-Arroyo et al. CURRENT PHARMACEUTICAL DESIGN
- A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference
- (2015) Paulus Kirchhof et al. EUROPACE
- Management of Atrial Fibrillation
- (2015) Talal Moukabary et al. MEDICAL CLINICS OF NORTH AMERICA
- Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
- (2014) Thitima Kongnakorn et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
- (2014) P. Dorian et al. EUROPEAN HEART JOURNAL
- Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
- (2014) Jelena Stevanović et al. PLoS One
- Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation
- (2014) Gregory Y.H. Lip et al. STROKE
- Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
- (2014) Tereza Lanitis et al. THROMBOSIS RESEARCH
- Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
- (2014) T. Lanitis et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) James V. Freeman et al. ANNALS OF INTERNAL MEDICINE
- Worldwide Epidemiology of Atrial Fibrillation
- (2013) Sumeet S. Chugh et al. CIRCULATION
- Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS 2 and CHA 2 DS 2 -VASc Scores in Patients With Atrial Fibrillation
- (2013) Gregory Y.H. Lip et al. Circulation-Arrhythmia and Electrophysiology
- Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation
- (2013) William J. Canestaro et al.
- Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models
- (2013) Brendan L. Limone et al. PLoS One
- Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) Amanda R. Harrington et al. STROKE
- Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia
- (2013) Zanfina Ademi et al. European Journal of Preventive Cardiology
- Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin
- (2012) Soyon Lee et al.
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillation
- (2012) et al. EUROPACE
- Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
- (2012) Renato D Lopes et al. LANCET
- Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
- (2012) Soyon Lee et al. PLoS One
- 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
- (2011) Valentin Fuster et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
- (2011) Edith Nutescu et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Catalogue of EQ-5D Scores for the United Kingdom
- (2011) Patrick W. Sullivan et al. MEDICAL DECISION MAKING
- Apixaban in Patients with Atrial Fibrillation
- (2011) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
- (2010) et al. EUROPACE
- In-hospital direct cost of acute ischemic and hemorrhagic stroke in Greece
- (2008) G. Gioldasis et al. ACTA NEUROLOGICA SCANDINAVICA
- Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
- (2008) CEREBROVASCULAR DISEASES
- Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation
- (2008) A. Ringborg et al. EUROPACE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now